Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Equity Average (2021 - 2025)

Prime Medicine filings provide 5 years of Equity Average readings, the most recent being $141.3 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 17.5% to $141.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $141.3 million, a 17.5% decrease, with the full-year FY2025 number at $137.0 million, down 4.26% from a year prior.
  • Equity Average hit $141.3 million in Q4 2025 for Prime Medicine, up from $111.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $297.5 million in Q1 2023 to a low of -$209.1 million in Q3 2022.
  • Median Equity Average over the past 5 years was $141.3 million (2025), compared with a mean of $91.0 million.
  • Biggest five-year swings in Equity Average: surged 284.13% in 2023 and later tumbled 61.9% in 2025.
  • Prime Medicine's Equity Average stood at -$125.3 million in 2021, then soared by 137.17% to $46.6 million in 2022, then surged by 250.99% to $163.5 million in 2023, then grew by 4.78% to $171.3 million in 2024, then decreased by 17.5% to $141.3 million in 2025.
  • The last three reported values for Equity Average were $141.3 million (Q4 2025), $111.3 million (Q3 2025), and $83.9 million (Q2 2025) per Business Quant data.